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The objective of this study was to determine, in an adolescent population, the prevalence of nonalcoholic fatty
liver disease (NAFLD) and the association of NAFLD and cardiovascular risk factors with carotid artery intima-
media thickness (IMT), a marker of subclinical atherosclerosis. The authors conducted a population-based study
among 642 randomly selected adolescents aged 11–13 years in Reggio Calabria, southern Italy, between
November 2007 and October 2008. Prevalences of overweight and obesity were 30.5% and 13.5%, respectively.
The overall prevalence of NAFLD was 12.5%, increasing to 23.0% in overweight/obese adolescents. In univariate
analysis, increased IMT was positively associated with the presence of NAFLD, body mass index (BMI), waist
circumference, systolic blood pressure (all P ’s < 0.001), diastolic blood pressure (P ¼ 0.006), c-glutamyl trans-
peptidase (P¼ 0.006), alanine aminotransferase (P¼ 0.007), and C-reactive protein (P¼ 0.008) and was inversely
associated with high density lipoprotein cholesterol (P < 0.001). In multivariate analysis, NAFLD (P ¼ 0.002), BMI
(P ¼ 0.004), waist circumference (P ¼ 0.003), and systolic blood pressure (P ¼ 0.005) retained signiﬁcant
associations. The authors conclude that NAFLD, BMI, waist circumference, and systolic blood pressure are in-
dependent markers of increased IMT in a random sample of adolescents.
adolescent; atherosclerosis; blood pressure; body mass index; fatty liver; liver diseases; obesity; sex
Abbreviations: CI, conﬁdence interval; HOMA-IR, homeostasis model assessment of insulin resistance; IMT, intima-media
thickness.
Nonalcoholic fatty liver disease (hereafter called fatty
liver disease) is a spectrum of clinicopathologic conditions
characterized by excessive accumulation of fat in the liver
parenchyma of patients who have no history of alcohol
abuse. Within this spectrum, steatosis alone is apparently
benign, while nonalcoholic steatohepatitis, including liver-
cell inflammation and fibrosis, may progress to cirrhosis,
liver failure, and hepatocellular carcinoma (1).
Fatty liver disease is strongly associated with obesity,
type 2 diabetes, and dyslipidemia, and most patients have
evidence of insulin resistance (2, 3). These are typical fea-
tures of the metabolic syndrome, and in fact, several authors
consider fatty liver disease to be the hepatic expression of
the metabolic syndrome (4). The constellation of metabolic
abnormalities that contribute to the definition of metabolic
syndrome are well-documented risk factors for cardiovascu-
lar disease (5).
Given that fatty liver disease is associated with the abnor-
malities of the metabolic syndrome, it would be important to
know whether fatty liver disease is an independent risk
factor for cardiovascular disease. Several studies have ad-
dressed this issue and found evidence that, indeed, fatty liver
disease is a significant risk factor for cardiovascular disease
(6–13). Most of these studies used as the outcome carotid
artery intima-media thickness (IMT) as a noninvasive
marker of subclinical atherosclerosis. Increased IMT is
associated with the presence and severity of coronary
atherosclerosis and cardiovascular disease (14–16).
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However, most studies examining the relation of fatty liver
disease to IMT have used a case-control design, which is
vulnerable to temporal and other biases. Only a very small
number of population-based studies have been reported
(13, 17). The few studies performed in adolescent popula-
tions (7, 18) have all been case-based, rather than population-
based, case-control studies.
Here we present results of a study carried out in randomly
selected adolescents from Reggio Calabria, a town in south-
ern Italy. The aim of the study was to determine the preva-
lence of fatty liver disease and its association with carotid
artery IMT. To our knowledge, this is the first study of its
kind to be performed in a general adolescent population.
MATERIALS AND METHODS
Setting and target population
The study was conducted by the Hepatology Association
of Calabria, in collaboration with the Istituto Superiore di
Sanita` (Italy’s Advanced Health Institute). The study pro-
tocol was approved by the ethics committees of the partici-
pating institutions.
The study was conducted from November 2007 through
October 2008 in Reggio Calabria, a town of approximately
185,000 inhabitants in the Calabria region of southern Italy.
A sample of 843 adolescents aged 11–13 years was ran-
domly selected from an updated school census list. Written
informed consent was obtained from the parents of all ado-
lescents who agreed to participate in the study.
Administration of questionnaire
At enrollment, a standardized, precoded questionnaire on
sociodemographic characteristics and medical history was
administered by trained health-care professionals. The ques-
tionnaire included questions on alcohol consumption—
specifically the type and amount of alcohol consumed and
the duration of consumption. Based on the alcohol content
of the beverages reported, mean daily alcohol intake was
calculated and expressed in grams per day. Participants who
consumed at least 12.5 g of alcohol per day (half the amount
considered the upper normal limit for adults (19)) and those
with chronic use of potentially hepatotoxic medications
were excluded from the analysis.
The questionnaire also included questions on smoking.
Eight subjects answered that they smoked but had not
smoked for longer than 1 year; and 5 of them claimed to
smoke occasionally, 3 on a regular basis, but not more than
10 cigarettes per day. Given the small number of smokers,
their recent initiation of smoking, and their relatively mod-
est use of cigarettes, we considered it unlikely that smoking
could represent a cardiovascular risk factor in these subjects.
Therefore, we did not consider smoking further in our
analysis.
No information about menarche status was collected.
Physical examination
Weight and height were measured without shoes and with
light clothing, and body mass index was calculated as body
weight (kg) divided by the square of height (m2). Waist
circumference was measured, during expiration, at the
narrowest point between the lower rib and the iliac crest.
Overweight and obesity were defined according to the In-
ternational Obesity Task Force criteria (20). Blood pressure
was measured 3 times, after the subject had been seated for
at least 10 minutes. The last 2 measurements were averaged
for analysis.
Biochemistry
Blood samples were collected in the morning after an
overnight fast. All blood tests were conducted in the same
laboratory. Blood was tested within a few hours of sampling.
Fasting levels of glucose, triglycerides, total cholesterol,
and high density lipoprotein cholesterol were determined
in dry chemistry on a Vitros 950 automatic analyzer (Ortho
Clinical Diagnostics, Raritan, New Jersey), and C-reactive
protein level was determined with the BN PROSPEC
nephelometer (Dade Behring Marburg GmbH, Marburg,
Germany). Insulin was measured by microparticle enzyme
immunoassay (Abbott Laboratories, Abbott Park, Illinois).
Low density lipoprotein cholesterol was calculated using the
formula of Friedewald (21). Insulin resistance (homeostasis
model assessment of insulin resistance (HOMA-IR)) was
calculated as insulin (mU/L) 3 [glucose (mg/dL) 3
0.055]/22.5 (22).
Liver ultrasonography
Adolescents underwent abdominal ultrasonography
according to a standardized protocol. Real-time ultrasonog-
raphy was performed using a MyLab 25 ultrasound scanner
(Esaote S.p.A., Genoa, Italy), with a 3.5-MHz convex
transducer. Technical parameters were optimized on
a case-by-case basis. All examinations were carried out
and interpreted by the same sonographer. Sonographic find-
ings were categorized into the presence or absence of stea-
tosis. Diagnosis of steatosis was based on the presence of
brightness with clear-cut sonographic contrast between the
liver and the right renal cortex in the midaxillary line,
according to international guidelines (23, 24). In cases of
uncertain diagnosis, additional criteria, such as vessel blur-
ring, posterior beam attenuation, and no visualization of
the diaphragm were used. No graduation in the severity of
steatosis was considered in this study.
Since the sonographer who assessed fatty liver disease
could not be blinded to the weight status of the study
subjects, she was asked to reexamine 100 anonymous
ultrasonograms after 1 month. The initial diagnoses were
confirmed.
Carotid artery ultrasonography
Carotid artery ultrasonography was performed using a
10-MHz linear transducer on the MyLab 25 scanner
(Esaote). The protocol involved scanning of both common
carotid arteries. Subjects were examined by 1 trained oper-
ator following a standardized protocol (25). Briefly, IMT
was assessed at the far wall as the distance between the
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leading edge of the first and second echogenic lines. All of
the scans were recorded. The best-quality end diastolic im-
age was captured in a longitudinal view that showed the
bifurcation and was analyzed off-line. From this image,
3 measurements of the common carotid artery were taken
at points 0.5 cm, 1 cm, and 2 cm below the bifurcation, and
the average measurement was used. All measurements were
carried out by a single sonographer on previously recorded
scans. At the time of reading, the sonographer was unaware
of the patients’ identities and characteristics. Repeated mea-
surements conducted by this sonographer in the same sub-
jects (30 obese, 30 overweight, and 30 normal, randomly
selected from the study children) gave an intraobserver
coefficient of variation of 3.3%.
Statistical analysis
Data were expressed as percentages, mean values (with
standard deviations), or median values (with 90% ranges).
Ninety-five percent confidence intervals were calculated for
proportions and means. Differences between groups were
analyzed with the Wilcoxon rank-sum test for medians,
the chi-squared test for proportions, and the t test for means.
Simple linear models were used to assess the crude associ-
ation of each predictor variable with IMT. Multiple regres-
sion models with IMT as the dependent variable were used
for multivariate adjustment of predictor variables that had
been shown to have P values less than 0.05 in univariate
analysis. Different multiple regression models were used for
each of the predictor variables that were highly correlated
(body mass index and waist circumference). Results were
defined as statistically significant when the P value (2-sided)
was less than 0.05.
RESULTS
Of the 843 randomly selected subjects, 646 (76.6%)
agreed to participate. Four subjects were excluded from
the analysis because of daily alcohol consumption exceed-
ing the predetermined limit (2 subjects) or chronic use of
potentially hepatotoxic medications (2 subjects, 1 taking an
antidepressant and the other taking an antiepileptic drug).
Of the remaining 642 subjects, 70 did not provide consent
for blood sampling. Females represented 50.6% of the study
population.
Characteristics of study participants are shown in Table 1.
According to International Obesity Task Force criteria,
30.5% (95% confidence interval (CI): 27.0, 34.3) of the
adolescents were overweight and 13.5% (95% CI: 11.0,
16.4) were obese. No difference in the prevalence of over-
weight was observed between the sexes (31.1% (95% CI:
26.1, 36.5) in boys vs. 29.9% (95% CI: 25.0, 35.2) in girls;
P ¼ 0.74), while obesity was especially prevalent in boys
(17.3% (95% CI: 13.3, 21.9) in boys vs. 9.9% (95% CI: 6.9,
13.7) in girls; P ¼ 0.006).
The overall prevalence of fatty liver disease (n ¼ 642)
was 12.5% (95% CI: 10.0, 15.3), and prevalence was higher
in boys than in girls (P ¼ 0.003) (Figure 1). There was
a graded relation between the prevalence of fatty liver dis-
ease and body mass index, with fatty liver disease reaching
values well over 40% (43.7%, 95% CI: 33.1, 54.7) in obese
Table 1. Characteristics of Study Participants (642 Randomly Selected Adolescents Aged 11–13 Years), Reggio
Calabria, Southern Italy, 2007–2008
Characteristic
No. of
Subjectsa
Mean (SD) Median 90% Range
Intima-media thickness, mm 642 0.397 (0.034) 0.40 0.34–0.46
Body mass indexb 642 21.3 (4.2) 20.7 15.7–29.5
Waist circumference, cm 641 79.3 (11.6) 78 63–99
Systolic blood pressure, mm Hg 642 105 (11.6) 105 87–124
Diastolic blood pressure, mm Hg 642 65 (7.9) 65 53–80
Alanine aminotransferase, IU/L 572 31 (8.4) 30 22–43
c-Glutamyl transpeptidase, IU/L 572 14 (5.1) 13 9–23
Total cholesterol, mg/dL 572 158 (26.5) 156 118–205
High density lipoprotein cholesterol,
mg/dL
572 51 (11.9) 50 34–73
Low density lipoprotein cholesterol,
mg/dL
572 92 (23.9) 89 60–134
Triglycerides, mg/dL 572 74 (35.5) 66 35–140
Glucose, mg/dL 572 83 (6.9) 82 72–94
Insulin, mIU/L 572 9.8 (6.6) 8.4 3.6–19.7
Homeostasis model assessment of
insulin resistance
572 2.0 (1.5) 1.6 0.7–4.2
C-reactive protein, mg/L 572 1.13 (2) 0.43 0.08–4.85
Abbreviation: SD, standard deviation.
a Of the 642 study subjects, 70 did not provide consent for blood sampling.
b Weight (kg)/height (m)2.
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adolescents. Notably, 7.3% (95% CI: 3.8, 12.4) of boys and
1.5% (95% CI: 0.3, 4.4) of girls (overall, 4.2% (95% CI: 2.4,
6.8)) with fatty liver disease had normal weight. Subjects
with fatty liver disease had significantly higher median body
mass index, waist circumference, alanine aminotransferase,
c-glutamyl transpeptidase, triglycerides, insulin, HOMA-
IR, C-reactive protein (all P’s < 0.001), systolic blood pres-
sure (P ¼ 0.01), and diastolic blood pressure (P ¼ 0.004)
than subjects without fatty liver disease (Table 2). Moreover,
adolescents with fatty liver disease had significantly lower
high density lipoprotein cholesterol levels than those with-
out fatty liver disease (P< 0.001). There were no significant
differences in total cholesterol, low density lipoprotein cho-
lesterol, or glucose concentrations by fatty liver disease
status.
The mean IMT in the study population was 0.397 mm
(95% CI: 0.395, 0.400), and IMTwas higher in males than in
females (mean IMT ¼ 0.402 mm (95% CI: 0.399, 0.406) in
boys vs. 0.392 mm (95% CI: 0.389, 0396) in girls; P <
0.001). IMT was higher in adolescents with fatty liver
disease than in those without fatty liver disease (mean
IMT ¼ 0.417 mm (95% CI: 0.409, 0.425) vs. 0.395 mm
(95% CI: 0.392, 0.397); P < 0.001).
Univariate analysis (Table 3) showed that the presence of
fatty liver disease, increased body mass index, waist circum-
ference, systolic blood pressure (all P’s < 0.001), diastolic
blood pressure (P ¼ 0.006), c-glutamyl transpeptidase
(P ¼ 0.006), alanine aminotransferase (P ¼ 0.007), and
C-reactive protein (P ¼ 0.008) were associated with in-
creased IMT. Only high density lipoprotein cholesterol
(P < 0.001) was inversely associated with IMT, while total
Figure 1. Prevalence of nonalcoholic fatty liver disease (NAFLD) in
study participants (642 randomly selected adolescents aged 11–13
years) by sex and body weight, Reggio Calabria, Southern Italy,
2007–2008.
Table 2. Characteristics of Study Participants According to the Absence or Presence of Nonalcoholic Fatty Liver
Disease, Reggio Calabria, Southern Italy, 2007–2008
Characteristic
No NAFLD NAFLD P
ValueaNo. Median 90% Range No. Median 90% Range
Body mass indexb 562 20.3 15.5–28.1 80 25.6 17.3–31.6 <0.001
Waist circumference, cm 561 76.5 62.5–97 80 90.3 69–104.3 <0.001
Systolic blood pressure,
mm Hg
562 105 87–124 80 109 90–125.5 0.01
Diastolic blood pressure,
mm Hg
562 64 53–79 80 67 52.5–82 0.004
Alanine aminotransferase,
IU/L
498 29 21–41 74 36 26–74 <0.001
c-Glutamyl transpeptidase,
IU/L
498 12 9–19 74 17 10–33 <0.001
Total cholesterol, mg/dL 498 156 119–205 74 154.5 115–217 0.73
High density lipoprotein
cholesterol, mg/dL
498 51 34–74 74 45 31–63 <0.001
Low density lipoprotein
cholesterol, mg/dL
498 88.5 60–133 74 89.5 56–146 0.23
Triglycerides, mg/dL 498 65.5 34–127 74 80 36–181 <0.001
Glucose, mg/dL 498 82 72–94 74 83 72–99 0.08
Insulin, mIU/L 498 7.7 3.4–17.7 74 12.6 4.6–33.2 <0.001
Homeostasis model
assessment of
insulin resistance
498 1.5 0.7–3.7 74 2.6 0.8–7.5 <0.001
C-reactive protein, mg/L 498 0.38 0.08–3.30 74 1.57 0.08–10.10 <0.001
Abbreviation: NAFLD, nonalcoholic fatty liver disease.
a Derived using the Wilcoxon rank-sum test.
b Weight (kg)/height (m)2.
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cholesterol, low density lipoprotein cholesterol, triglycer-
ides, glucose, insulin, and HOMA-IR were not associated
with increased IMT.
After adjustment for confounders in the multivariate anal-
ysis (Table 4), only fatty liver disease (difference in IMT
with the presence of fatty liver disease ¼ 0.0147 mm (95%
CI: 0.0054, 0.0240)), body mass index (difference per unit
increase ¼ 0.0011 mm (95% CI: 0.0003, 0.0019)), waist
circumference (difference per 1-cm increase ¼ 0.0004 mm
(95% CI: 0.0001, 0.0007)), and systolic blood pressure
Table 3. Crude Association Between Characteristics of Study Participants and Intima-Media Thickness, Reggio
Calabria, Southern Italy, 2007–2008
Characteristic
No. of
Subjects
ba
95% Conﬁdence
Interval
P
Value
Presence of nonalcoholic fatty
liver disease (vs. absence)
642 0.0221 0.0143, 0.0299 <0.001
Body mass indexb 642 0.0019 0.0013, 0.0025 <0.001
Waist circumference, cm 641 0.0007 0.0005, 0.0009 <0.001
Systolic blood pressure, mm Hg 642 0.0006 0.0003, 0.0008 <0.001
Diastolic blood pressure, mm Hg 642 0.0005 0.0001, 0.0008 0.006
Alanine aminotransferase, IU/L 572 0.0005 0.0001, 0.0008 0.007
c-Glutamyl transpeptidase, IU/L 572 0.0008 0.0002, 0.0013 0.006
Total cholesterol, mg/dL 572 0.0001 0.0002, 0.0000 0.158
High density lipoprotein
cholesterol, mg/dL
572 0.0004 0.0006, 0.0002 <0.001
Low density lipoprotein
cholesterol, mg/dL
572 0.00002 0.00014, 0.00010 0.722
Triglycerides, mg/dL 572 0.00005 0.00003, 0.00013 0.214
Glucose, mg/dL 572 0.0003 0.0001, 0.0007 0.149
Insulin, mIU/L 572 0.0003 0.0001, 0.0007 0.149
Homeostasis model assessment
of insulin resistance
572 0.0013 0.0005, 0.0032 0.164
C-reactive protein, mg/L 572 0.0019 0.0005, 0.0033 0.008
a Regression coefﬁcients represent, for the dichotomous variable (nonalcoholic fatty liver disease), the average
difference in intima-media thickness (mm) as compared with the reference group and, for continuous variables, the
change in intima-media thickness (mm) per unit increase in the characteristic.
b Weight (kg)/height (m)2.
Table 4. Multivariate Analysis of Relations Between Selected Clinical Characteristics of Participants and Intima-
Media Thickness (n ¼ 572), Reggio Calabria, Southern Italy, 2007–2008
Characteristic ba
95% Conﬁdence
Interval
P
Value
Presence of nonalcoholic fatty
liver disease (vs. absence)
0.0147 0.0054, 0.0240 0.002
Body mass indexb,c 0.0011 0.0003, 0.0019 0.004
Waist circumference, cmc 0.0004 0.0001, 0.0007 0.003
Alanine aminotransferase, IU/L 0.0000 0.0004, 0.0004 0.836
c-Glutamyl transpeptidase, IU/L 0.0001 0.0008, 0.0005 0.662
High density lipoprotein cholesterol 0.0001 0.0004, 0.0001 0.263
C-reactive protein, mg/dL 0.0001 0.0016, 0.0014 0.868
Systolic blood pressure, mm Hg 0.0004 0.0001, 0.0007 0.005
Diastolic blood pressure, mm Hg 0.0001 0.0005, 0.0003 0.613
a Regression coefﬁcients represent the average estimated increase in intima-media thickness (mm) per unit in-
crease in the characteristic or the presence (vs. absence) of the characteristic. Results were simultaneously and
reciprocally adjusted for all other variables shown in the table (except waist circumference) and for sex.
b Weight (kg)/height (m)2.
c Body mass index and waist circumference were added independently to the model because of the high corre-
lation between these 2 variables.
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(difference per 1-mm Hg increase ¼ 0.0004 mm (95%
CI: 0.0001, 0.0007)) remained significantly associated
with IMT.
DISCUSSION
The prevalence of overweight and obesity among adoles-
cents in our study population (44.1%, 95% CI: 40.2, 48.0)
was very high. It was roughly similar to the prevalence
reported for other pediatric populations in southern Italy
(26, 27) and in the United States, where the levels of child-
hood overweight and obesity are among the highest
recorded in the world (28).
The present data on fatty liver disease are among the few
that have been reported for an adolescent population in the
age range of 12–13 years. We found an overall prevalence of
ultrasonographically diagnosed ‘‘bright liver’’ of 12.5%
(95% CI: 10.0, 15.3), which could not be attributed to
excessive alcohol consumption or intake of medications
potentially steatogenic to the liver.
Not surprisingly, the prevalence of fatty liver disease
increased progressively from normal-weight subjects to
overweight subjects to obese subjects, affecting almost 1
in 2 adolescents within the latter category. In fact, fatty
liver disease is strongly associated with overweight/obesity
(29–32) and other markers of the metabolic syndrome
(6, 33–35) and is now considered by many investigators
to be the hepatic expression of the metabolic syndrome
(4, 36, 37).
In a previous study, the prevalence of fatty liver disease
was determined ultrasonographically in a population of 810
northern Japanese children (38). The overall prevalence of
fatty liver disease was 2.6% and was higher for boys (3.4%)
than for girls (1.8%), although the difference was not statis-
tically significant. Fatty liver disease was found in children
as young as 6 years of age. Zhou et al. (39) published a report
on the prevalence of fatty liver disease in a general popula-
tion in southern China. The overall study population
of 3,543 subjects included 379 children and youths aged
7–18 years. The prevalence of fatty liver disease in this
age group, determined by real-time ultrasonography, was
1.3% and was 3 times higher for boys (1.9%) than for girls
(0.6%). Imhof et al. (40) studied a population-based sample
of 378 adolescents aged 12–20 years who were randomly
selected from the general population of a small town in
southern Germany. The prevalence of fatty liver disease in
these study participants was approximately 5%, almost all
of it found among overweight/obese subjects.
Thus, the prevalence of fatty liver disease in our study
appears to be the highest reported so far for an adolescent
population. This is not unexpected in view of the very high
prevalence of overweight and obesity in our study popula-
tion and the close association of these conditions with fatty
liver disease. It should also be considered that the preva-
lence of fatty liver disease that we found is a likely under-
estimation of the true, histologically defined prevalence of
fatty liver disease. In fact, mild forms of fatty liver disease
cannot be visualized by echography, because this method
does not reliably detect steatosis affecting less than 33% of
hepatocytes (23).
Another main objective of the present study was to iden-
tify increased carotid artery IMT as an early marker of
atherosclerosis and to verify whether cardiovascular risk
factors or components of the metabolic syndrome and fatty
liver disease are associated with increased IMT in our sam-
ple. Increased IMT has been associated with cardiovascular
risk factors as well as the presence and severity of coronary
atherosclerosis and cardiovascular disease (16, 41, 42). It
has also been reported in children with diabetes, hyperten-
sion, and obesity (43, 44). In particular, several studies com-
paring obese and nonobese children have found significant
differences in IMT (45, 46).
We found that increased body mass index or waist cir-
cumference, systolic blood pressure, and the presence of
fatty liver disease were independently associated with in-
creased IMT, allowing us to consider them as markers of
increased IMT and cardiovascular risk. To our knowledge,
this is the first report of an independent association between
fatty liver disease and increased IMT in a population-based
study of adolescent subjects.
The difference in IMT between subjects with and without
fatty liver disease was narrow (median value of 0.417 mm
(95% CI: 0.0.409, 0.425) vs. 0.395 mm (95% CI: 0.392,
0397); P < 0.001). Nevertheless, our results show that fatty
liver disease is a highly significant marker of increased IMT.
As regards a possible link between fatty liver disease and
increased IMTand cardiovascular risk, it has been suggested
that fatty liver disease might contribute to accelerated ath-
erosclerosis through increased oxidative stress, chronic sub-
clinical inflammation, and decreased liver production of
cytokines with antiatherogenic properties (8).
Regarding the other factors that were independently as-
sociated with increased IMT, several articles in the literature
have reported associations of body mass index (47, 48) and/
or systolic blood pressure (49–51) with increased IMT, in
adults as well as adolescents. Reducing systolic blood pres-
sure has even been shown to result in regression of carotid
IMT and a decrease in left ventricular mass among persons
with type 2 diabetes (52). On the other hand, it is surprising
that components of the metabolic syndrome (5), such as
dyslipidemia, elevated fasting glucose levels, and insulin
resistance—which are established risk factors for cardiovas-
cular disease—did not show a significant association with
increased IMT in our study.
There are different possible explanations for this lack of
association. Some risk factors may only affect IMT upon
prolonged cumulative exposure, which may not have oc-
curred in our participants, given their young ages (51).
Moreover, as other investigators have already discussed
(53), changes in carotid IMT may not reflect the effects of
all cardiovascular risk factors. That is, not all cardiovascular
risk factors may cause increased IMT; rather, they may
affect later stages of the atherosclerotic process, such as
plaque formation.
Our study presents some limitations that should be con-
sidered: its cross-sectional nature, which precluded the pos-
sibility of establishing temporal relations, and the lack of
biopsy-proven fatty liver disease, which made it impossible
to evaluate the association of IMT with severity of liver
disease. In addition, we did not test for hepatitis B virus
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or hepatitis C virus, since vaccination against the former is
mandatory in Italy and the prevalence of the latter was ex-
pected to be extremely low in the age group included in our
study. Indeed, in a previous study from our group performed
in a geographic area close to Reggio Calabria (54), we could
not identify a single adolescent with hepatitis C virus in-
fection. Among the strengths of this study was the relatively
large sample size (appropriate for studying a continuous
outcome such as IMT), its novelty, and the consideration
of important confounding factors.
Notwithstanding its limitations, our study showed a high
prevalence of fatty liver disease in a sample of adolescents
from southern Italy and identified fatty liver disease, body
mass index, and systolic blood pressure as independent
markers for increased IMT.
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